291O DESTINY-Breast11: Neoadjuvant trastuzumab deruxtecan alone (T-DXd) or followed by paclitaxel + trastuzumab + pertuzumab (T-DXd-THP) vs SOC for high-risk HER2+ early breast cancer (eBC)

N. Harbeck, S. Modi, L. Pusztai, Shinji Ohno, J. Wu, S.B. Kim, Alessandra Fabi, Xuchen Cao, Riya Joseph, Rong Li, Bogdan Żurawski, Santiago Escrivá-de-Romaní, S.C. Chen, C. Kelly, G. Curigliano, F Symmans, S. Mondal, S. Safdar, P. Herbolsheimer, J-F. Boileau